Screener / SEC EDGAR /CIK 0001609550 /10-K filed Feb 13, 2026, compared with Feb 10, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Inspire Medical Systems, Inc. INSP

Compare with peers Embed
What it said it expected, against what it reported

3 targets with a reported result

Releases of the last 3 years
Above the range 3 above the last range given
Within the range 0 of 3 range targets
Below the range 0 below the last range given

The numbers INSP said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Capital expenditures (company-defined)
Fiscal 2026
Given $45.00M to $50.00M release Feb 11, 2026
Lowered $40.00M to $45.00M release May 4, 2026
Lowered $35.00M to $40.00M release Aug 3, 2026
Kept $35.00M to $40.00M release Nov 2, 2026
– No standard number
The company's words
Full Year 2026 Outlook … The Company’s outlook assumes an effective tax rate of approximately 44% to 49% and an adjusted effective tax rate of 26% to 28%, estimated weighted average diluted shares outstanding of approximately 29.4 million and capital expenditures between $45 million to $50 million. release Feb 11, 2026
Full Year 2026 Guidance … The Company’s outlook assumes an effective tax rate of approximately 65% to 70% and an adjusted effective tax rate of 27% to 29%, estimated weighted average diluted shares outstanding of approximately 29.4 million, and capital expenditures between $40 million to $45 million. release May 4, 2026
Full Year 2026 Guidance … The Company’s outlook assumes an effective tax rate of approximately 95% to 100% and an adjusted effective tax rate of 30% to 35%, estimated weighted average diluted shares outstanding of approximately 29.4 million, and capital expenditures between $35 million to $40 million. release Aug 3, 2026
Full Year 2026 Guidance … The Company’s outlook assumes an effective tax rate of approximately 120% to 175% and an adjusted effective tax rate of 33% to 34%, estimated weighted average diluted shares outstanding of approximately 28.9 million, and capital expenditures between $35 million to $40 million. release Nov 2, 2026
Capital expenditures
Fiscal 2026
Given $45.00M to $50.00M release Feb 11, 2026
Lowered $40.00M to $45.00M release May 4, 2026
Lowered $35.00M to $40.00M release Aug 3, 2026
Kept $35.00M to $40.00M release Nov 2, 2026
– Not reported yet
The company's words
Full Year 2026 Outlook … The Company’s outlook assumes an effective tax rate of approximately 44% to 49% and an adjusted effective tax rate of 26% to 28%, estimated weighted average diluted shares outstanding of approximately 29.4 million and capital expenditures between $45 million to $50 million. release Feb 11, 2026
Full Year 2026 Guidance … The Company’s outlook assumes an effective tax rate of approximately 65% to 70% and an adjusted effective tax rate of 27% to 29%, estimated weighted average diluted shares outstanding of approximately 29.4 million, and capital expenditures between $40 million to $45 million. release May 4, 2026
Full Year 2026 Guidance … The Company’s outlook assumes an effective tax rate of approximately 95% to 100% and an adjusted effective tax rate of 30% to 35%, estimated weighted average diluted shares outstanding of approximately 29.4 million, and capital expenditures between $35 million to $40 million. release Aug 3, 2026
Full Year 2026 Guidance … The Company’s outlook assumes an effective tax rate of approximately 120% to 175% and an adjusted effective tax rate of 33% to 34%, estimated weighted average diluted shares outstanding of approximately 28.9 million, and capital expenditures between $35 million to $40 million. release Nov 2, 2026
Diluted EPS (company-defined)
Fiscal 2026
Given $1.23 to $1.81 release Feb 11, 2026
Lowered $1.05 to $1.45 release Aug 3, 2026
Raised $1.20 to $1.40 release Nov 2, 2026
– No standard number
The company's words
Full Year 2026 Outlook … Additionally, the Company expects annual adjusted operating margin in the range of 6% to 8%, net income per diluted share in the range of $1.23 to $1.81 and adjusted net income per diluted share in the range of $1.85 to $2.35. release Feb 11, 2026
Full Year 2026 Guidance … Additionally, the Company now expects annual adjusted operating margin to be in the range of 4% to 6%, diluted EPS to be in the range of $(0.42) to $0.17 and adjusted diluted EPS to be in the range of $1.05 to $1.45. release Aug 3, 2026
Full Year 2026 Guidance … Additionally, the Company now expects adjusted operating margin to be in the range of 4.5% to 5.5%, diluted EPS to be in the range of $(0.36) to $(0.10) and adjusted diluted EPS to be in the range of $1.20 to $1.40. release Nov 2, 2026
Diluted EPS
Fiscal 2026
Given $1.23 to $1.81 release Feb 11, 2026
– Not reported yet
The company's words
Full Year 2026 Outlook … Additionally, the Company expects annual adjusted operating margin in the range of 6% to 8%, net income per diluted share in the range of $1.23 to $1.81 and adjusted net income per diluted share in the range of $1.85 to $2.35. release Feb 11, 2026
Revenue
Fiscal 2026
Given $1.00B to $1.01B release Jan 12, 2026
Lowered $950.00M to $1.00B release Feb 11, 2026
Lowered $825.00M to $875.00M release May 4, 2026
Raised $835.00M to $875.00M release Aug 3, 2026
Narrowed $850.00M to $860.00M release Nov 2, 2026
– Not reported yet
The company's words
Revenue for full year 2026 is anticipated to be in the range of $1,003 million to $1,013 million, a 10% to 11% increase over full year 2025 release Jan 12, 2026
Full Year 2026 Outlook … The Company is revising its previously announced revenue outlook to be in the range of $950 million to $1.0 billion, which represents expected annual growth of 4% to 10%. release Feb 11, 2026
Full Year 2026 Guidance … The Company is revising its previously announced revenue outlook to be in the range of $825 million to $875 million, which represents a decline of 4% to 10% compared to 2025. release May 4, 2026
Full Year 2026 Guidance … The Company is raising its previously announced revenue outlook to be in the range of $835 million to $875 million. release Aug 3, 2026
Full Year 2026 Guidance … The Company is narrowing its previously announced revenue outlook to be in the range of $850 million to $860 million, compared to the previous range of $835 million to $875 million. release Nov 2, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $940.00M to $955.00M release Jan 13, 2025
Kept $940.00M to $955.00M release Feb 10, 2025
Kept $940.00M to $955.00M release May 5, 2025
Lowered $900.00M to $910.00M release Aug 4, 2025
Kept $900.00M to $910.00M release Nov 3, 2025
$911.98M
10-K filed 2026-02-13
Above the range
The company's words
Revenue for full year 2025 is anticipated to be in the range of $940 million to $955 million, a 17% to 19% increase over full year 2024 release Jan 13, 2025
Reaffirms full year 2025 revenue to be in the range of $940 million to $955 million, which would represent year-over-year growth of approximately 17% to 19% release Feb 10, 2025
Inspire is maintaining its full year 2025 revenue guidance of between $940 million to $955 million, which represents growth of 17% to 19% over full year 2024 revenue of $802.8 million. release May 5, 2025
Inspire currently anticipates full year 2025 revenue guidance to be in the range of $900 million to $910 million, which represents growth of 12% to 13% over full year 2024 revenue of $802.8 million. release Aug 4, 2025
Recent field experience with the Inspire V system is generating very positive feedback from clinicians, and the team is making excellent progress with the U.S. launch with over 75% of centers ready to transition to Inspire V. We remain laser-focused on execution and with our strong performance and disciplined investments and cost management, we are reaffirming our full year revenue guidance of $900 to $910 million and increasing our diluted net income per share guidance to $0.90 to $1.00, up from $0.40 to $0.50 previously. release Nov 3, 2025
Diluted EPS
Fiscal 2024 (ended Dec 31, 2024)
Given $0.60 to $0.80 release Aug 6, 2024
Raised $1.20 to $1.40 release Nov 4, 2024
$1.75
10-K filed 2025-02-10
Above the range
The company's words
Inspire is increasing diluted net income per share guidance for the full year 2024 to between $0.60 to $0.80 per share, excluding the impact of any share repurchases that may be effected during the year. release Aug 6, 2024
“Based on the strength of our business, we are increasing our full year revenue guidance to $793 million to $798 million, from $788 million to $798 million previously, and we are raising our full year earnings per share guidance to $1.20 to $1.40, up from $0.60 to $0.80 previously.” release Nov 4, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $775.00M to $785.00M release Jan 8, 2024
Kept $775.00M to $785.00M release Feb 6, 2024
Raised $783.00M to $793.00M release May 7, 2024
Raised $788.00M to $798.00M release Jul 29, 2024
Kept $788.00M to $798.00M release Aug 6, 2024
Raised $793.00M to $798.00M release Nov 4, 2024
$802.80M
10-K filed 2025-02-10
Above the range
The company's words
Revenue for full year 2024 is anticipated to be in the range of $775 million to $785 million, a 24% to 26% increase over full year 2023 release Jan 8, 2024
Reaffirms full year 2024 revenue to be in the range of $775 million to $785 million, which would represent year-over-year growth of approximately 24% to 26% release Feb 6, 2024
Inspire is increasing its full year 2024 revenue guidance to between $783 million to $793 million, which represents growth of 25% to 27% over full year 2023 revenue of $624.8 million. release May 7, 2024
Revenue for full year 2024 is anticipated to be in the range of $788 million to $798 million, which represents growth of 26% to 28% over full year 2023. release Jul 29, 2024
“Based on our strong first half results, we are increasing our full year revenue guidance to $788 million to $798 million, representing 26% to 28% growth, up from of $783 million to $793 million announced previously, and we are raising our full year earnings per share guidance to $0.60 to $0.80, up from $0.10 to $0.20 previously.” release Aug 6, 2024
“Based on the strength of our business, we are increasing our full year revenue guidance to $793 million to $798 million, from $788 million to $798 million previously, and we are raising our full year earnings per share guidance to $1.20 to $1.40, up from $0.60 to $0.80 previously.” release Nov 4, 2024
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)
  • Diluted EPS, Fiscal 2025 (ended Dec 31, 2025): said $0.90 to $1.00, reported $4.89. The company's words

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (16 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSP/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.